AbbVie Skyrizi achieves 35.8% endoscopic remission in Phase 3 Crohn’s disease study
New Phase 3 AFFIRM data show 35.8% endoscopic remission and 36.6% ulcer-free endoscopy with subcutaneous Skyrizi at Week 24. The findings support regulatory applications for an alternative to intravenous induction, although differences in treatment allocation after Week 12 require careful interpretation.